Gilead Sciences (GILD) Income from Non-Controlling Interests (2009 - 2023)

Gilead Sciences (GILD) reported Income from Non-Controlling Interests of -$12.0 million for Q4 2023, down 71.43% on a YoY basis from -$42.0 million in Q4 2022, and down 50.0% quarter-over-quarter from -$8.0 million in Q3 2023.

Gilead Sciences (GILD) Income from Non-Controlling Interests (2009 - 2023) Analysis & Trends

Gilead Sciences has reported Income from Non-Controlling Interests for 15 years, with the latest figure at -$12.0 million in Q4 2023.

  • For the quarter ending Q4 2023, Income from Non-Controlling Interests fell 71.43% year-over-year to -$12.0 million; the trailing twelve-month figure through Sep 2024 stood at -$12.0 million (up 74.47% YoY), and the FY2023 full-year result was -$52.0 million, down 100.0% from the prior year.
  • Income from Non-Controlling Interests for Q4 2023 stood at -$12.0 million, down from -$8.0 million in the prior quarter.
  • The five-year high for Income from Non-Controlling Interests was -$3.0 million in Q3 2019, with the low at -$26.0 million in Q1 2023.
  • Historically, Income from Non-Controlling Interests has averaged -$7.9 million across 5 years, with a median of -$7.0 million in 2019.
  • Annual changes were most pronounced in 2019 — Income from Non-Controlling Interests plunged 800.0% — and 2022, when it jumped 50.0%.
  • Gilead Sciences' Income from Non-Controlling Interests stood at -$7.0 million in 2019, then changed by 0.0% to -$7.0 million in 2020, then increased by 14.29% to -$6.0 million in 2021, then fell by 16.67% to -$7.0 million in 2022, then sank by 71.43% to -$12.0 million in 2023.
  • The last three Income from Non-Controlling Interests figures came in at -$12.0 million (Q4 2023), -$8.0 million (Q3 2023), and -$6.0 million (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 2.48 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn -
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn -
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 2.00 Mn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn -3.00 Mn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn -
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn -
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 8.00 Mn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 1.00 Mn
10 Novartis Ag 109.78 Bn 109.09 Bn - 415.00 Mn

Historic Data

Download Data
DateValue
Dec 31, 2023 -12.00 Mn
Sep 30, 2023 -8.00 Mn
Jun 30, 2023 -6.00 Mn
Mar 31, 2023 -26.00 Mn
Dec 31, 2022 -7.00 Mn
Sep 30, 2022 -3.00 Mn
Jun 30, 2022 -9.00 Mn
Mar 31, 2022 -7.00 Mn
Dec 31, 2021 -6.00 Mn
Sep 30, 2021 -6.00 Mn
Jun 30, 2021 -5.00 Mn
Mar 31, 2021 -7.00 Mn
Dec 31, 2020 -7.00 Mn
Sep 30, 2020 -7.00 Mn
Jun 30, 2020 -7.00 Mn
Mar 31, 2020 -13.00 Mn
Dec 31, 2019 -7.00 Mn
Sep 30, 2019 -3.00 Mn
Jun 30, 2019 -5.00 Mn
Mar 31, 2019 -7.00 Mn